News | June 17, 2023
MoS Health addresses TB Health Technologies workshop
Urges Innovators to produce quality products that can be deployed at scale
Urges Innovators to produce quality products that can be deployed at scale
The company has now received the Establishment Inspection Report (EIR) indicating closure of the inspection
Collaboration to accelerate and de-risk clinical development of Nanopharmaceutics CNS portfolio
Pfizer is likely to show GSK significant competition
The randomised, multi-centre, evaluator blinded, parallel group, active controlled Phase 3 trial is being led by Lanhzou Biotechnique Development
Chinook Therapeutics is a clinical-stage biopharmaceutical company with two high-value, late-stage assets in development for IgA nephropathy (IgAN), a rare, progressive chronic kidney disease
Injectafer is now the first and only intravenous (IV) iron replacement therapy indicated for adult patients with heart failure who have iron deficiency
Olverembatinib is the first and only third-generation BCR-ABL inhibitor approved in China for the treatment of adult patients with tyrosine kinase inhibitors
The US FDA in its communication mentioned it may withhold approval of any pending applications or supplements in which this facility is listed.
The target boundary includes biogenic land?related emissions and removals from bioenergy feedstock
Subscribe To Our Newsletter & Stay Updated
